Kelly Godby is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 124 publications with 4,173 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
619 19th St S
Birmingham, AL 352491900
Telephone
205-934-5038Registry record last updated 29 Jun 2023.
Clinical trials
- Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Sponsor: Susan Bal
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
- Tempus AI, IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27.1%Opioid Agonist12.4%Oxycodone Hcl52%Oxycodone-Acetaminophen22%Tramadol Hcl11%Oxycontin8%Methadone Hcl6%Part D<11 patientsGabapentinoids7%Gabapentin90%Pregabalin10%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
20.8%Thalidomide Analog18.8%Revlimid41%Lenalidomide35%Pomalyst24%Part D≥29 patientsProteasome Inhibitor1.3%Ninlaro100%Part D<11 patients+ 1 more class in this area
Dermatology
16.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.7%Acyclovir100%Part D≥71 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis
Journal of Cachexia Sarcopenia and Muscle
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”